Abstract library

391 results for "breast cancer".
#716 Adrenal Metastases and Neuroendocrine Breast Carcinoma in a MEN-1 Patient
Introduction: In Multiple Endocrine Neoplasia type 1 (MEN-1) pituitary, parathyroid and pancreatic/duodenal endocrine cells are typically involved. Other neoplasms also occur.
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: professor Claudio Pasquali
#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy
Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Alma Demirović
#247 Carcinoid Metastases to the Breast: More Common than Previously Thought. A Presentation of 13 Cases
Introduction: Metastases from carcinoid tumors to the breast have been described as a rare phenomenon. Presentation and cytopathologic findings of these tumors can closely mimic that of a mammary carcinoma.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Joakim Crona
#553 Neuroendocrine and Ductal Breast Cancer Coexistence: An Unusual Case Report
Introduction: Breast Primary Neuroendocrine carcinoma (BNEC) is a rare entity. Literature surveillance reveal few cases with no well-established therapeutic options. We herein report a case.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Nektarios Alevizopoulos
Keywords: breast, NET, endocrine
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#2154 Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer
Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Alexey Ivanov
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#1443 Second Primary Malignancies Incidence in Patients with Neuroendocrine Tumours – Retrospective Review of 454 Neuroendocrine Tumour Cases
Introduction: Increased incidence of second primary malignancies (SPM) in patients (pts) with neuroendocrine tumors (NET) has been reported.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj
#1112 Second Primary Malignancies in Patients with Neuroendocrine Tumors
Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Ashley Clift
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
Authors: Schmid H A, Chiara L, Nuciforo P, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.